Autolus Therapeutics to Present Positive Results from its Phase 2 FELIX study in adult r/r B-ALL at ASCO

(24/7 MARKET NEWS) – Autolus Therapeutics plc (NASDAQ: AUTL) stated, this morning, that it will present top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Autolus Therapeutics is trading at $3.28, up $0.15 (+4.79%), on 90.02K premarket shares traded.

Its 52-week range is $1.60 to $3.79. If this breaks through the May 23 $3.45 resistance on strong trading volume, this could hit new 52-week highs.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist